Alnuctamab  (Synonyms: EM901; CC-93269)

Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)^[1][2][3].

Human IgG1 kappa/lambda

Human IgG1 kappa, Isotype Control

Alnuctamab (72 h) 在 T 细胞和 BCMA⁺ 的骨髓瘤细胞系 (H929、OPM-2、L363) 共培养体系中，与 CELMoD 药物 (Pomalidomide (HY-10984)、Mezigdomide (HY-129395) 和 Iberdomide (HY-101291) 联用，增强了 T 细胞介导的肿瘤细胞杀伤效力，表现为 IC₅₀ 值降低和多发性骨髓瘤细胞清除率增加^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Alnuctamab 在植入 H929 骨髓瘤细胞的免疫缺陷小鼠中，与 Mezigdomide (HY-129395) 连用，显著抑制肿瘤生长，增强 T 细胞 (尤其是 CD8⁺ 细胞) 浸润肿瘤，增加肿瘤内 T 细胞活化标志物 (如 CD69) 表达^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

192.13 kDa

2296827-07-9

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa/lambda with domain crossover, trivalent

• 
  Immobilized CD3 epsilon/CD3e Protein can bind Alnuctamab. The EC₅₀ for this effect is 0.728 ng/mL.
• 
  Immobilized BCMA/TNFRSF17 Protein, Human can bind Alnuctamab. The EC₅₀ for this effect is 0.051 ng/mL.

• [1]. Paiva B, et al. Synergistic antitumor activity of alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+ 1 T cell engager (TCE), and celmod agents in multiple myeloma (MM) preclinical models. Blood, 2022, 140(Supplement 1): 7054-7055.

  [2]. Wong S W, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study[J]. Blood, 2022, 140(Supplement 1): 400-402.

  [3]. Danny V Jeyaraju, et al. Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs). Blood (2022) 140 (Supplement 1): 7070–7071.